Canaccord Genuity on Life Sciences/Specialty Pharma: Top Summer Catalyst-Driven Ideas To Trump 'Macro' Influence
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $40.23 +0.68%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade TEVA Now!
Canaccord Genuity on Life Sciences/Specialty Pharma: Top Summer Catalyst-Driven Ideas To Trump 'Macro' Influence
Analyst, Randall Stanicky, said, "Broader market sentiment is clearly challenging, which was apparent in investor meetings we held in four different cities over the last week. We expect uncertainty linked to a host of issues including health reform (within the next week), macro/EU challenges (unlikely to fade), summer lull and November election to continue to impact volumes and stocks. That said, we do see opportunity for single-stock performance in catalyst-driven names where events will outweigh macro over the next three months. There are several stocks with major events but our top two catalyst-driven names are Teva Pharma (Nasdaq: TEVA) and Impax (Nasdaq: IPXL) (both BUY). BUY-rated Warner Chilcott (Nasdaq: WCRX) brings potential for upside given its ongoing review of strategic alternatives on admittedly low visibility but with little priced in given the recent pull-back."
TEVA (BUY, $52 PT) - Copaxone trial decision imminent and the most important catalyst
IPXL (BUY, $29 PT) – Top small cap idea with three catalysts set to come near-term
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Randall Stanicky, said, "Broader market sentiment is clearly challenging, which was apparent in investor meetings we held in four different cities over the last week. We expect uncertainty linked to a host of issues including health reform (within the next week), macro/EU challenges (unlikely to fade), summer lull and November election to continue to impact volumes and stocks. That said, we do see opportunity for single-stock performance in catalyst-driven names where events will outweigh macro over the next three months. There are several stocks with major events but our top two catalyst-driven names are Teva Pharma (Nasdaq: TEVA) and Impax (Nasdaq: IPXL) (both BUY). BUY-rated Warner Chilcott (Nasdaq: WCRX) brings potential for upside given its ongoing review of strategic alternatives on admittedly low visibility but with little priced in given the recent pull-back."
TEVA (BUY, $52 PT) - Copaxone trial decision imminent and the most important catalyst
IPXL (BUY, $29 PT) – Top small cap idea with three catalysts set to come near-term
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Apple (AAPL) Streaming Music Service Could be Delayed - The Verge
- SolarCity (SCTY) is 'Hot, Hot, Hot', But Questions About Financing Deal Raised
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
